CPT.L Regulatory News (CPT)

RNS release: 25.10.19, 7:00am

Concepta PLC

("Concepta" or the "Company")

Board Changes

Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®") the most accurate home-use fertility tracking and pregnancy testing system available on the U.K. market, announces today the appointment of Mrs Madeleine ("Maddy") Kennedy FCCA, as Chief Financial Officer and Director on the Concepta PLC board. She replaces Barbara Spurrier who has today left the Board to spend more time on her other business interests.

Maddy Kennedy has previously acted as interim CFO for Ieso Digital Health and PsiOxus Therapeutics, was CFO for Lab21 and Finance Director at Alliance Pharma plc, taking it through its IPO. She specialises in growing life science businesses and has more than 20 years' experience in the sector, both in public and private companies.

Matthew Walls, Chairman, commented "We would like to thank Barbara for her kind help and support to the business as CFO since Concepta effected the reverse takeover in 2016 and we are delighted to welcome Maddy to the Concepta PLC Board."

The following disclosures are made in line with the AIM Rules for Companies:

Madeleine's full name is Madeleine Elizabeth Kennedy, she is 54 years old.

Current directorships/partnerships:

MadJak Associates Limited

Directorships and partnerships held within the last five years:

Ingleby (1879) Limited

Emac Limited

The Market Bosworth School

Vanir Consultants Limited

Shareholding : Mrs Kennedy holds no shares in the Company.

Save for the information set out above, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Mrs Kennedy.

Enquiries:

About Concepta PLC (www.conceptaplc.com)

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

myLotus® is the most accurate home-use fertility tracking and pregnancy testing system available on the U.K. market and is the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.